Skip to main content
Carisma Therapeutics Inc. logo

Carisma Therapeutics Inc. — Investor Relations & Filings

Ticker · CARM ISIN · US14216R1014 LEI · 549300DGKHONOZQIY116 US Manufacturing
Open in API
Filings indexed 853 across all filing types
Latest filing 2025-12-29 Regulatory Filings
Country US United States of America
Listing US CARM

About Carisma Therapeutics Inc.

https://sesenbio.com/

Carisma Therapeutics Inc. is a clinical-stage biotechnology company pioneering the development of engineered macrophage-based therapeutics. The company's proprietary cell therapy platform is centered on Chimeric Antigen Receptor Macrophages (CAR-M) and CAR-Monocytes. This approach is designed to leverage the unique abilities of macrophages to infiltrate solid tumors, overcome the immunosuppressive tumor microenvironment, and stimulate a broad anti-tumor response. Carisma's pipeline is focused on developing treatments for cancer and other serious disorders, including fibrosis.

Recent filings

Filing Released Lang Actions
15-12G
Regulatory Filings Classification · 100% confidence The document is a Form 15 filed with the SEC, titled 'Certification and Notice of Termination of Registration under Section 12(g) of the Securities Exchange Act of 1934 or Suspension of Duty to File Reports under Sections 13 and 15(d)'. It is a regulatory filing notifying the termination or suspension of reporting obligations. The document is short (1878 characters) and contains a certification by an officer. It does not contain financial statements or detailed financial data. Therefore, it is not an annual report, interim report, or earnings release. It is a regulatory filing related to compliance and reporting status. According to the classification rules, such filings fall under Regulatory Filings (RNS).
2025-12-29 English
Regulatory Filings 2025
Regulatory Filings
2025-12-17 English
Regulatory Filings 2025
Regulatory Filings
2025-12-17 English
Regulatory Filings 2025
Regulatory Filings
2025-12-17 English
Regulatory Filings 2025
Regulatory Filings
2025-12-17 English
S-8 POS
Transaction in Own Shares Classification · 95% confidence The document is a Post-Effective Amendment to multiple Form S-8 Registration Statements filed with the SEC. Form S-8 is used for registering securities to be offered under employee benefit plans, such as stock incentive plans and employee stock purchase plans. The document details the deregistration of unsold or unissued shares under these registration statements, effectively terminating the effectiveness of these filings. This type of filing is related to share repurchase or deregistration of shares, which aligns with the category of Transaction in Own Shares (POS). The document is not a financial report, earnings release, or management discussion, but a regulatory filing concerning share deregistration. Therefore, the appropriate classification is POS with high confidence.
2025-12-15 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.